Y Benderli Cihan1, K Deniz2, H Mutlu3, B Kaplan4. 1. Radiation Oncology Department of Kayseri Education and Research Hospital, Kayseri, Turkey. 2. Pathology Department of Erciyes University Medical School, Kayseri, Turkey. 3. Medical Oncology Department of Acıbadem Hospitals, Kayseri, Turkey. 4. Radiation Oncology Department of Erciyes University Medical School, Kayseri, Turkey.
Abstract
AIM: This study was to investigate whether the use of hormonotherapy after concurrent radiotherapy (RT) and trastuzumab (T) has a contribution to the development of radiation fibrosis in the lungs. MATERIALS AND METHODS: Seventy Wistar Albino rats were divided into seven groups as follows: Group C: control, Group RT: RT only; Group T: trastuzumab only; Group RT+T+Tam: tamoxifen following concurrent RT and trastuzumab; Group RT+T+Le: letrozole following concurrent RT and trastuzumab; Group RT+T+An: anastrazole following concurrent RT and trastuzumab; Group RT+T+Exe: exemestane following concurrent RT and trastuzumab. Trastuzumab was prepared at an equivalent dose of 6 mg/kg. RT was administered 2 hours after T to the thoracic region at a dose of 12 Gy. Hormonotherapy was initiated one week after RT and administered by oral gavage once daily for 6 months. At the end of 24 weeks, the rats were sacrificed after being sedated with anesthesia. Both lungs were removed en bloc and blocked in paraffin. The level of fibrosis in each cross-section was assessed with the help of a scale. RESULTS: Significant differences were observed between the groups in terms of pulmonary fibrosis scoring. Statistically significant differences were observed when the radiotherapy group was compared to the C, T, T+RT+An, T+RT+Le and T+RT+Exe groups (p<0.05). Significant differences were found between the T+RT+Tam group and the C, T, T+RT+An, T+RT+Le and T+RT+Exe groups (p<0.05). CONCLUSIONS: This study showed that the sequential administration of aromatase inhibitors following concurrent thoracic irradiation and T decreases radiation-induced pulmonary fibrosis. However, tamoxifen was found to have an opposite effect.
AIM: This study was to investigate whether the use of hormonotherapy after concurrent radiotherapy (RT) and trastuzumab (T) has a contribution to the development of radiation fibrosis in the lungs. MATERIALS AND METHODS: Seventy Wistar Albino rats were divided into seven groups as follows: Group C: control, Group RT: RT only; Group T: trastuzumab only; Group RT+T+Tam: tamoxifen following concurrent RT and trastuzumab; Group RT+T+Le: letrozole following concurrent RT and trastuzumab; Group RT+T+An: anastrazole following concurrent RT and trastuzumab; Group RT+T+Exe: exemestane following concurrent RT and trastuzumab. Trastuzumab was prepared at an equivalent dose of 6 mg/kg. RT was administered 2 hours after T to the thoracic region at a dose of 12 Gy. Hormonotherapy was initiated one week after RT and administered by oral gavage once daily for 6 months. At the end of 24 weeks, the rats were sacrificed after being sedated with anesthesia. Both lungs were removed en bloc and blocked in paraffin. The level of fibrosis in each cross-section was assessed with the help of a scale. RESULTS: Significant differences were observed between the groups in terms of pulmonary fibrosis scoring. Statistically significant differences were observed when the radiotherapy group was compared to the C, T, T+RT+An, T+RT+Le and T+RT+Exe groups (p<0.05). Significant differences were found between the T+RT+Tam group and the C, T, T+RT+An, T+RT+Le and T+RT+Exe groups (p<0.05). CONCLUSIONS: This study showed that the sequential administration of aromatase inhibitors following concurrent thoracic irradiation and T decreases radiation-induced pulmonary fibrosis. However, tamoxifen was found to have an opposite effect.
Authors: Vladimir Valakh; Mark G Trombetta; E D Werts; George Labban; Mian K Khalid; Anna Kaminsky; David Parda Journal: Am J Clin Oncol Date: 2011-06 Impact factor: 2.339
Authors: Nuran Senel Bese; Cenk Umay; Sukru Yildirim; Sennur Ilvan; Ahmet Dirican; Seda Salar; Tuncay Altug; Ahmet Ober Journal: Breast Date: 2005-08-02 Impact factor: 4.380
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: David Azria; Yazid Belkacemi; Gilles Romieu; Sophie Gourgou; Marian Gutowski; Khalil Zaman; Carmen Llacer Moscardo; Claire Lemanski; Michael Coelho; Barry Rosenstein; Pascal Fenoglietto; Nigel E A Crompton; Mahmut Ozsahin Journal: Lancet Oncol Date: 2010-02-06 Impact factor: 41.316
Authors: Y Belkacémi; J Gligorov; M Ozsahin; H Marsiglia; B De Lafontan; H Laharie-Mineur; L Aimard; E-C Antoine; B Cutuli; M Namer; D Azria Journal: Ann Oncol Date: 2008-03-15 Impact factor: 32.976